MX2020013181A - Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. - Google Patents
Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.Info
- Publication number
- MX2020013181A MX2020013181A MX2020013181A MX2020013181A MX2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A
- Authority
- MX
- Mexico
- Prior art keywords
- administering
- compound
- patient
- thiazolidine
- dione
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona métodos para tratar una enfermedad o trastorno en un paciente que comprende administrar 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-ti azolidin-2,4-diona ("Compuesto (1)"), o una sal farmacéuticamente aceptable de la misma, al paciente, en donde el paciente logra una concentración plasmática umbral de estado estacionario del Compuesto (1). La presente descripción también proporciona métodos para administrar una cantidad terapéuticamente efectiva del compuesto (1), o una sal farmacéuticamente aceptable del mismo, a un paciente. El compuesto (1) es un agonista de PPAR-? que se usa para tratar una variedad de enfermedades y trastornos que incluyen, pero no se limitan a, esteatohepatitis no alcohólica y enfermedades de sistema nervioso central, por ejemplo, adrenoleucodistrofia enlazada a X, ataxia de Friedreich.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382398 | 2018-06-06 | ||
| PCT/IB2019/054743 WO2019234689A1 (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013181A true MX2020013181A (es) | 2021-02-26 |
Family
ID=62716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013181A MX2020013181A (es) | 2018-06-06 | 2019-06-06 | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210308113A1 (es) |
| EP (1) | EP3801516A1 (es) |
| JP (1) | JP7549344B2 (es) |
| KR (1) | KR20210031435A (es) |
| CN (1) | CN112512524A (es) |
| AU (1) | AU2019283649A1 (es) |
| BR (1) | BR112020024917A2 (es) |
| CA (1) | CA3102407A1 (es) |
| CL (1) | CL2020003162A1 (es) |
| EA (1) | EA202092953A1 (es) |
| IL (1) | IL279183A (es) |
| MX (1) | MX2020013181A (es) |
| SG (1) | SG11202012045UA (es) |
| WO (1) | WO2019234689A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| JP7376934B2 (ja) | 2018-06-06 | 2023-11-09 | ミノリックス セラピューティクス エセ．エレ． | ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩 |
| WO2024141951A1 (en) | 2022-12-28 | 2024-07-04 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006320633A1 (en) | 2005-11-29 | 2007-06-07 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
| ES2872335T3 (es) | 2014-04-02 | 2021-11-02 | Minoryx Therapeutics S L | Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central |
| JP7294661B2 (ja) | 2016-12-23 | 2023-06-20 | ミノリックス セラピューティクス エセ．エレ． | ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス |
-
2019
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en active Pending
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
- 2019-06-06 US US16/972,368 patent/US20210308113A1/en active Pending
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en unknown
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko unknown
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt unknown
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 JP JP2020567799A patent/JP7549344B2/ja active Active
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL279183A (en) | 2021-01-31 |
| BR112020024917A2 (pt) | 2021-03-09 |
| JP2021527045A (ja) | 2021-10-11 |
| WO2019234689A1 (en) | 2019-12-12 |
| EA202092953A1 (ru) | 2021-04-12 |
| CL2020003162A1 (es) | 2021-07-02 |
| CN112512524A (zh) | 2021-03-16 |
| KR20210031435A (ko) | 2021-03-19 |
| EP3801516A1 (en) | 2021-04-14 |
| US20210308113A1 (en) | 2021-10-07 |
| CA3102407A1 (en) | 2019-12-12 |
| JP7549344B2 (ja) | 2024-09-11 |
| SG11202012045UA (en) | 2021-01-28 |
| AU2019283649A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013181A (es) | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. | |
| CL2021000491A1 (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| JP2014528486A5 (es) | ||
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| JP2010525056A5 (es) | ||
| CN107693518A (zh) | Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途 | |
| HUP0300479A2 (hu) | PPAR-gamma agonisták alkalmazása neutrofil okozta betegségek kezelésére | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| EA201991078A1 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| US20190216804A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis | |
| EA200701680A1 (ru) | Лекарственная форма для перорального введения, содержащая розиглитазон | |
| CO5261586A1 (es) | Uso de pramipexol en el tratamiento de transtornos de adiccion | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| MXPA04000839A (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| CA2907049A1 (en) | Use of ep4 receptor antagonists in the treatment of cartilage disease | |
| JP2009532438A5 (es) | ||
| MX2013008715A (es) | Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco. | |
| CY1124116T1 (el) | 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος | |
| EP1758998A4 (en) | OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES | |
| RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
| JP2007538064A (ja) | 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法 |